Journal
CANCER
Volume 123, Issue -, Pages 2104-2117Publisher
WILEY
DOI: 10.1002/cncr.30593
Keywords
driver mutations; genetics; immune therapy; melanoma; targeted therapy
Categories
Funding
- Lubax
- Epiphany Dermatology
- British Journal of Dermatology
Ask authors/readers for more resources
Melanoma has one of the highest somatic mutational burdens among solid malignancies. Although the rapid progress in genomic research has contributed immensely to our understanding of the pathogenesis of melanoma, the clinical significance of the vast array of genomic alterations discovered by next-generation sequencing is far from being fully characterized. Most mutations prevalent in melanoma are simply neutral passengers, which accompany functionally significant drivers under transforming conditions. The delineation of driver mutations from passenger mutations is critical to the development of targeted therapies. Novel advances in genomic data analysis have aided in distinguishing true driver mutations involved in tumor progression. Here, the authors review the current literature on important somatic driver mutations in melanoma, along with the implications for treatment. (c) 2017 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available